In two reports published this fall in collaboration with the laboratory of former Abbott lab post-doc Dr. Zhaoyang Hu, it is shown that the SGLT2 inhibitor empagliflozin protects the heart against sudden cardiac death, and the lungs against ischemia/reperfusion injury, even in nondiabetic animal models. These findings potentially broaden the clinical indications for empagliflozin.
EmpagliflozinProtects against Pulmonary Ischemia/Reperfusion Injury via an ERK1/2-Dependent Mechanism.
Huang D, Ju F, Du L, Liu T, Zuo Y, Abbott GW, Hu Z. J Pharmacol Exp Ther. 2021 Dec 10:JPET-AR-2021-000956. doi: 10.1124/jpet.121.000956. Online ahead of print.PMID: 34893552
https://pubmed.ncbi.nlm.nih.gov/34893552
Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death.
Hu Z, Ju F, Du L, Abbott GW. Cardiovasc Diabetol. 2021 Oct 4;20(1):199. doi: 10.1186/s12933-021-01392-6.PMID: 34607570